ALCHEMIST: Adjuvant targeted therapy or immunotherapy for high-risk resected NSCLC.

被引：0
|
作者：
Sands, Jacob
Mandrekar, Sumithra J.
Oxnard, Geoffrey R.
Kozono, David E.
Hillman, Shauna L.
Dahlberg, Suzanne Eleanor
Sun, Zhuoxin
Chaft, Jamie E.
Govindan, Ramaswamy
Gerber, David E.
Gray, Jhanelle Elaine
Malik, Shakun M.
Mooney, Margaret M.
Janne, Pasi A.
Vokes, Everett E.
Kelly, Karen
Ramalingam, Suresh S.
Stinchcombe, Tom
机构：
[1] Lahey Hosp & Med Ctr, Boston, MA USA
[2] Mayo Clin, Rochester, MN USA
[3] Dana Farber Canc Inst, Boston, MA 02115 USA
[4] IBCSG Stat Ctr, Boston, MA USA
[5] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA
[6] Washington Univ, Sch Med, St Louis, MO USA
[7] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[8] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA
[9] NCI, Rockville, MD USA
[10] Univ Chicago Med, Dept Med, Sect Hematol Oncol, Chicago, IL USA
[11] Univ Calif Davis, Comprehens Canc Ctr, Sacramento, CA 95817 USA
[12] Emory Univ Hosp, Winship Canc Inst, 1364 Clifton Rd NE, Atlanta, GA 30322 USA
[13] Duke Canc Inst, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期
基金：
美国国家卫生研究院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS9077
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Adjuvant targeted therapy for resected NSCLC: to be or not to be?
    Ye, Ting
    Chen, Haiquan
    JOURNAL OF THORACIC DISEASE, 2018, 10 : S3297 - S3299
  • [2] Adjuvant Targeted Therapy Following Standard Adjuvant Therapy for Resected NSCLC: An Initial Report from ALCHEMIST (Alliance A151216)
    Oxnard, G.
    Mandrekar, S.
    Hillman, S.
    Tan, A.
    Govindan, R.
    Wigle, D.
    Malik, S.
    Watt, C.
    Gerber, D.
    Chaft, J.
    Dahlberg, S.
    Kelly, K.
    Faggen, M.
    Stella, P.
    Tazi, K.
    Gandara, D.
    Ramalingam, S.
    Stinchcombe, T.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S646 - S647
  • [3] Adjuvant therapy for resected high-risk melanoma
    Moser, Justin C.
    Grossmann, Kenneth F.
    SEMINARS IN CUTANEOUS MEDICINE AND SURGERY, 2018, 37 (02) : 109 - 111
  • [4] Adjuvant Immunotherapy and Radiation in the Management of High-risk Resected Melanoma
    Gonzalez, Ricardo J.
    Kudchadkar, Ragini
    Rao, Nikhil G.
    Sondak, Vernon K.
    OCHSNER JOURNAL, 2010, 10 (02): : 108 - 116
  • [5] Adjuvant therapy for resectable NSCLC.
    Douillard, JY
    Delgado, FM
    Larriba, JL
    Rosell, R
    De Lena, M
    Rodrigues, J
    Carpagnano, F
    Danel, P
    Kolek, V
    Biville, F
    BRITISH JOURNAL OF CANCER, 1998, 78 : 34 - 34
  • [6] Adjuvant therapy for high-risk primary and resected metastatic melanoma
    Hersey, P
    INTERNAL MEDICINE JOURNAL, 2003, 33 (1-2) : 33 - 43
  • [7] High-risk surgically resected pediatric melanoma and adjuvant interferon therapy
    Chao, MM
    Schwartz, JL
    Wechsler, DS
    Thornburg, CD
    Griffith, KA
    Williams, JA
    PEDIATRIC BLOOD & CANCER, 2005, 44 (05) : 441 - 448
  • [8] Does Adjuvant Therapy for High-Risk Melanoma With Either Immunotherapy or Targeted Therapy Affect Therapeutic Choices at Relapse?
    Postow, Michael A.
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (05) : 353 - 355
  • [9] The case for adjuvant BRAF-targeted therapy versus adjuvant anti-PD-1 therapy for patients with resected, high-risk melanoma
    Mooradian, Meghan J. J.
    Sullivan, Ryan J. J.
    CANCER, 2023, 129 (14) : 2117 - 2121
  • [10] Utilization and survival benefit of adjuvant immunotherapy in resected high-risk stage II melanoma
    Wong, William G.
    Holguin, Rolfy A. Perez
    Stahl, Kelly A.
    Olecki, Elizabeth J.
    Pameijer, Colette
    Shen, Chan
    SURGERY IN PRACTICE AND SCIENCE, 2022, 8
12345